R Squared’s Neurocrine Biosciences NBIX Stock Holding History

R Squared’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-450	Closed	-$61.4K	–	1048
2024 Q4	$61.4K	Buy	+450	New	+$55.7K	0.06%	420

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

R Squared's NBIX Position: Q1 2025 in Review

R Squared sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 450 shares — an estimated $61.4K sold.

R Squared first reported a position in NBIX in Q4 2024 and held it in 1 quarter. The position peaked at $61.4K in Q4 2024. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

R Squared reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
R Squared sold 450 Neurocrine Biosciences shares in Q1 2025, an estimated $61.4K.
R Squared first reported a position in Neurocrine Biosciences in Q4 2024 and held it in 1 quarter.
R Squared's Neurocrine Biosciences position peaked at $61.4K in Q4 2024.
586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.